Science & Technology
Science and Technology
Science and Technology
Tue, June 2, 2009
Mon, June 1, 2009
Sun, May 31, 2009
Active Biotech: Active Biotech Completes Patient Enrollment to ANYARA Phase III Clinical Trial
LUND, SWEDEN--(Marketwire - June 1, 2009) - Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that patient enrollment to the Phase III clinical trial for ANYARA, a novel compound for the treatment of renal cell cancer, is completed after enrollment of over 500 patients into the study.
This pivotal Phase III study evaluates the efficacy and safety of ANYARA in combination with interferon-alfa compared to interferon-alfa alone, in patients with advanced renal cell cancer. The primary clinical efficacy parameter is overall survival.
Final survival data for ANYARA will be analyzed after 384 events and the current estimate is that these will be presented by the end of 2010/beginning of 2011.
Lund 1 June 2009 Active Biotech AB (publ) Tomas Leanderson President & CEO
About ANYARA
ANYARA is a TTS (Tumor Targeting Superantigens) compound that makes the treatment of cancer tumor-specific. The development of ANYARA is mainly focused on renal cell cancer. Positive data was reported in connection with the interim analysis in Phase II/III and from clinical Phase I trials in lung cancer, renal cell cancer and pancreatic cancer. The median survival of 26.2 months observed for patients with advanced renal cancer and treated with ANYARA is twice the expected length. ANYARA has been granted orphan-drug status by the EMEA for the indication renal cancer. Information concerning the ongoing clinical trial is available at [ www.activebiotech.com ] and [ www.clinicaltrials.gov ].
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex™ for RA. Please visit [ www.activebiotech.com ] for more information.
Active Biotech AB PO Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08:30 am CET on June 1, 2009.
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
